2003059599

09 OCT 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092091 A1

(51) International Patent Classification[7]: A61K 31/506, A61P 35/00, 37/06 // (A61K 31/506, 31:675) (A61K 31/506, 31:4196) (A61K 31/506, 31:704) (A61K 31/506, 31:337)

(21) International Application Number: PCT/EP02/05362

(22) International Filing Date: 15 May 2002 (15.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/291,427 16 May 2001 (16.05.2001) US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRUNS, Christian** [DE/DE]; Ziegelhofstrasse 120, 79110 Freiburg (DE). **BUCHDUNGER, Elisabeth** [DE/DE]; Saegeweg 13, 79395 Neuenburg (DE). **O'REILLY, Terence** [CA/CH]; Drahtzugstrasse 51, CH-4057 Basel (CH). **SILBERMAN, Sandra, Leta** [US/US]; 10 Heather Lane, Randolph, NJ 07869 (US). **WARTMANN, Markus** [CH/CH]; Kornfeldstrasse 14, CH-4125 Riehen (CH). **WECKBECKER, Gisbert** [DE/CH]; Löliring 31, CH-4105 Biel-Benken (CH).

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



162162



ACTION

WO 02/092091 A1

(54) Title: COMBINATION COMPRISING N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT

(57) Abstract: A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.